Abstract
The interface between the pharmaceutical industry and public sector research (PSR) is increasingly diverse, dynamic and complex. As the industry consolidates at the top end, it is also differentiating and fragmenting. A new layer of small focused-activity companies are emerging, many from PSR. This paper examines patterns of knowledge exchange between PSR and industry along the length of the innovation chain, and the management of intellectual property rights.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
